Civil Rights
Movements, leaders, victories and the continuing fight for equality.
Explore the people, places, events, achievements, struggles and stories that shaped our journey.
Movements, leaders, victories and the continuing fight for equality.
Innovation, patents, science, technology and world-changing contributions.
Pioneers, champions, Negro Leagues, records, activism and excellence.
Meet the people whose lives, choices and achievements shaped the journey.
Black towns, communities, institutions and places where history happened.
Moments that changed communities, movements, institutions and the nation.
Wilmington, North Carolina once had a thriving Black middle class and an elected interracial government. In 1898 white supremacists used violence to overthrow that government, kill Black residents and drive many others from the city.
MORE →Reflects the personal views, recollections, and perspective of the author, Mike Davis.
This is a personal recollection on the Move fire on May 13, 1985
| Discipline | Oncology |
|---|---|
| Language | English |
| Edited by | Benjamin Bonavida |
| Publication details | |
| History | 1989–present |
| Publisher | |
| Frequency | Quarterly |
| Standard abbreviations | |
| ISO 4 | Crit. Rev. Oncog. |
| Indexing | |
| CODEN | CRONEI |
| ISSN | 0893-9675 |
| OCLC no. | 15716210 |
| Links | |
Critical Reviews in Oncogenesis is a quarterly scientific journal published by Begell House covering the field of oncology. The editor-in-chief is Benjamin Bonavida.
Source: Wikipedia. Article content is retrieved live through the MediaWiki API.
Critical Reviews in Oncogenesis is a quarterly scientific journal published by Begell House covering the field of oncology. The editor-in-chief is Benjamin Bonavida.
Oncogenesis is a peer-reviewed open access medical journal covering the molecular biology of cancer. It was established in 2012 by Douglas R. Green as a sister journal to Oncogene, of which Green was then editor-in-chief. New articles are published exclusively online by Springer Nature on a weekly basis. The editor-in-chief is Jan Paul Medema (University of Amsterdam). According to the Journal Citation Reports, the journal has a 2020 impact factor of 7.485, ranking it 40th out of 242 journals in the category "Oncology".
Crizotinib, sold under the brand name Xalkori among others, is an anti-cancer medication used for the treatment of non-small cell lung carcinoma (NSCLC). Crizotinib inhibits the c-Met/Hepatocyte growth factor receptor (HGFR) tyrosine kinase, which is involved in the oncogenesis of a number of other histological forms of malignant neoplasms. It also acts as an ALK (anaplastic lymphoma kinase) and ROS1 (c-ros oncogene 1) inhibitor.
Dihexa (developmental code PNB-0408; also known as N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is an oligopeptide drug derived from angiotensin IV that binds with high affinity to hepatocyte growth factor (HGF) and potentiates its activity at its receptor, c-Met. The compound has been found to potently improve cognitive function in animal models of Alzheimer's disease-like mental impairment. In an assay of neurotrophic activity, dihexa was found to be seven orders of magnitude more potent than brain-derived neurotrophic factor. According to a patent, "Short duration safety studies with dihexa have uncovered no apparent toxicity. Of particular note is a lack of neoplastic induction, since c-Met is recognized as an oncogene. This is unsurprising since oncogenesis requires multiple mutations including both oncogene induction and tumor suppressor attenuation."
Before the 1921 destruction of Tulsa’s Greenwood District, Black residents had created a remarkable center of business and community life. The district included stores, professional offices, entertainment venues and homes owned by Black citizens. Understanding Greenwood means learning what was built—not only what was burned.
MORE →Joe Louis.